Phase 2 Study of Fisetin Treatment for Older Adults with Mild Alzheimers Disease or Mild Cognitive Impairment

What this Trial Is About

Researchers are evaluating the safety and tolerability of a natural health product called fisetin in older adults diagnosed with mild cognitive impairment or mild Alzheimers disease dementia. This pilot study aims to better understand how fisetin may affect individuals with these neurocognitive conditions. The study is sponsored by Sunnybrook Health Sciences Centre and is conducted as a Phase 2 clinical trial. Participants will receive fisetin at a dose of 20 mg per kilogram of body weight daily. The study focuses on monitoring adverse events related to the treatment over a period of 30 days. There is no placebo or comparison group mentioned, and the study is not blinded. The intervention is designed to assess safety rather than effectiveness at this stage. During the study, participants will be observed for any treatment-emergent adverse events to determine fisetins safety and tolerability. Assessments include cognitive tests such as the MoCA score, and researchers will monitor participants overall health to ensure it is safe to continue. The total participation time for outcome measurement is 30 days, with follow-up to track any emerging issues during this period.

Fisetin in Mild Alzheimer's Disease